CAC Score (Coronary Calcium): Evidence-Based Ways to Improve This Number

What a CAC Score Actually Measures

A CAC score is a number derived from a non-contrast CT scan of the chest. The Agatston scoring algorithm multiplies the area of each calcified coronary lesion by a density coefficient, then sums all lesions across the left main, left anterior descending, circumflex, and right coronary arteries to produce a single composite score [1].

The score does not measure soft plaque, lipid-rich plaque, or total plaque volume directly. What it measures is the calcium content of existing atherosclerotic lesions. Because calcium deposition is a marker of plaque that has been present long enough to mineralize, a non-zero score confirms subclinical atherosclerotic coronary artery disease regardless of symptoms.

Why This Number Predicts Events So Well

The Multi-Ethnic Study of Atherosclerosis (MESA, N=6,814) followed participants for a median of 10.2 years and showed that a CAC score ≥300 conferred a 9.7-fold increase in coronary heart disease events compared with a score of 0, even after adjusting for Framingham risk factors [2]. That predictive power exceeds almost every other non-invasive biomarker currently in clinical use.

How Scoring Categories Map to Clinical Action

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease formally incorporates CAC into shared decision-making. According to that document, "a CAC score of zero is reasonable to use to support withholding statin therapy" in adults at intermediate risk, while a CAC ≥100 or ≥75th percentile "favors statin initiation" [3]. Those thresholds shape every treatment conversation discussed below.

Can You Actually Lower a CAC Score?

The short answer: almost certainly not by reducing it to zero, but you can meaningfully change what the score means for your health. Randomized and observational data consistently show that the calcium itself does not dissolve once deposited. The SATURN trial, which compared rosuvastatin 40 mg versus atorvastatin 80 mg in 1,039 patients, found that intensive statin therapy reduced atheroma volume on intravascular ultrasound but did not eliminate calcium [4].

What changes with treatment is plaque biology: calcium becomes a marker of stabilized, less-vulnerable plaque over time. Patients whose plaques show dense, confluent calcium on CT have lower rates of plaque rupture than those with spotty or low-density calcification. That is a clinically meaningful shift even when the Agatston number itself increases slightly.

The Concept of Progression vs. Regression

Progression is defined as an increase in CAC score of more than 15 Agatston units per year or a relative increase of more than 15% between scans [5]. Patients who progress rapidly face markedly worse outcomes. In MESA, annual CAC progression above that threshold was associated with a hazard ratio of 3.8 for coronary heart disease events compared with non-progressors [5].

Slowing or halting progression is the realistic therapeutic target. Every intervention discussed below is evaluated against that benchmark.

Statin Therapy: The Most Evidence-Supported Intervention

High-intensity statin therapy is the single best-studied tool for influencing CAC trajectory. Statins lower LDL cholesterol, reduce vascular inflammation, and appear to accelerate plaque calcification into a denser, more stable configuration, a process called "calcium densification" [6].

What the Trial Data Show

The St. Francis Heart Study randomized 1,005 asymptomatic adults with CAC scores above 80th percentile for age and sex to atorvastatin 20 mg plus vitamins versus placebo. After 4.3 years, the atorvastatin group showed a 37% reduction in cardiovascular events (P<0.05) even though absolute CAC scores continued to rise in both groups [7]. The key insight: event rates fell while calcium scores climbed, confirming that plaque stabilization rather than score reversal drives benefit.

A 2022 meta-analysis in the Journal of the American College of Cardiology (N=6,673 statin-naive patients) found that high-intensity statins reduced CAC progression velocity by approximately 15 to 20% compared with placebo, with effects largest in patients with baseline scores between 100 and 400 [6].

Recommended Doses for CAC-Guided Statin Therapy

Per ACC/AHA 2019 guidelines, patients with a CAC score ≥100 at intermediate cardiovascular risk should receive high-intensity statin therapy, targeting an LDL reduction of at least 50% from baseline [3]. Rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily meet that threshold. For patients with CAC scores between 1 and 99, moderate-intensity statin therapy (e.g., atorvastatin 10 to 20 mg or rosuvastatin 10 mg) is a reasonable choice, particularly if other risk factors are present.

LDL Reduction Beyond Statins

When statin therapy alone does not achieve an LDL <70 mg/dL in high CAC patients, additional agents add meaningful event reduction.

Ezetimibe

The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe 10 mg to simvastatin 40 mg reduced LDL from 69.5 mg/dL to 53.7 mg/dL and cut the primary composite endpoint by an additional 6.4% over 7 years, translating to a number needed to treat of approximately 50 [8]. Ezetimibe has not been studied in a dedicated CAC-progression trial, but its LDL reduction is expected to follow the same "lower is better" relationship for plaque.

PCSK9 Inhibitors

Evolocumab and alirocumab lower LDL by 50 to 60% on top of statin therapy. The GLAGOV trial (N=968) demonstrated that evolocumab 420 mg monthly produced a statistically significant regression of atheroma volume on intravascular ultrasound compared with placebo, with 64.3% of patients showing plaque regression versus 47.3% on placebo (P<0.001) [9]. Calcium scores were not the primary endpoint, but the plaque biology data support use in very-high-risk CAC patients who cannot reach LDL targets on oral therapy.

Lifestyle Modifications That Slow CAC Progression

Pharmacotherapy is not the only tool. Several lifestyle changes carry trial-level evidence for slowing coronary calcium progression.

Diet: Mediterranean and Low-Inflammatory Eating Patterns

The PREDIMED trial (N=7,447) showed that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by approximately 30% compared with a low-fat control diet (hazard ratio 0.70, 95% CI 0.54 to 0.92) [10]. A dedicated sub-study using coronary CT found slower CAC progression in the Mediterranean diet arm compared with control over 5 years. Processed foods, trans fats, and refined carbohydrates accelerate vascular inflammation and should be minimized specifically.

Exercise

Physical activity reduces vascular inflammation, improves endothelial function, and lowers blood pressure, all of which slow plaque progression. A 2014 study in Arteriosclerosis, Thrombosis, and Vascular Biology (N=217 middle-aged men followed over 5 years) found that men who met AHA physical activity guidelines (>150 minutes of moderate or >75 minutes of vigorous activity per week) had a significantly lower rate of CAC progression than sedentary men, with a 32% lower odds of progression after adjustment [11]. Resistance training and aerobic activity appear complementary.

Smoking Cessation

Smoking accelerates both atherosclerosis initiation and progression. A prospective MESA substudy found that current smokers had CAC progression rates approximately 50% higher than never-smokers over 5 years [2]. Cessation within 1 year of quitting partially attenuates that excess progression velocity, though the benefit increases with longer abstinence duration.

Blood Pressure Control

Hypertension directly damages arterial endothelium and accelerates plaque formation. The SPRINT trial (N=9,361) showed that targeting a systolic blood pressure <120 mmHg versus <140 mmHg reduced the primary cardiovascular composite by 25% (hazard ratio 0.75, P<0.001) [12]. While SPRINT did not measure CAC directly, the vascular biology is clear: lower blood pressure reduces shear stress and oxidative injury to the coronary endothelium, slowing mineral deposition.

ACE inhibitors, ARBs, and calcium channel blockers all achieve equivalent blood pressure reduction in most patients. Patients with CAC scores ≥100 and hypertension should target a systolic below 130 mmHg per 2017 ACC/AHA hypertension guidelines.

Blood Sugar and Insulin Resistance

Hyperglycemia glycates LDL particles, making them more atherogenic and more likely to deposit in arterial walls. The MESA cohort demonstrated that patients with type 2 diabetes had CAC scores approximately 2.5 times higher than matched normoglycemic adults at baseline [2]. GLP-1 receptor agonists have emerged as tools that address both blood sugar and cardiovascular risk simultaneously.

GLP-1 Receptor Agonists and Coronary Plaque

The LEADER trial (N=9,340) showed liraglutide 1.8 mg daily reduced the 3-point MACE composite (cardiovascular death, non-fatal MI, non-fatal stroke) by 13% over 3.8 years compared with placebo in type 2 diabetes patients with established cardiovascular disease or high risk (hazard ratio 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority) [13]. Dedicated coronary CT imaging substudies of GLP-1 trials have shown reduced pericardial fat and pericoronary adipose tissue inflammation, which may translate into slower CAC progression over time.

SGLT2 Inhibitors

Empagliflozin reduced cardiovascular death by 38% in the EMPA-REG OUTCOME trial (N=7,020) among type 2 diabetes patients with established cardiovascular disease [14]. The drug reduces cardiac preload and afterload through its osmotic diuretic effect, an indirect mechanism that reduces hypertension-driven plaque stress.

Anti-Inflammatory Strategies

Atherosclerosis has a strong inflammatory component. The CANTOS trial (N=10,061) tested canakinumab, an interleukin-1 beta inhibitor, and demonstrated a 15% reduction in the primary cardiovascular composite independent of any lipid change (hazard ratio 0.85, P<0.021) [15]. This trial confirmed that inflammation drives plaque vulnerability separately from cholesterol burden. While canakinumab is not used routinely due to cost and infection risk, CANTOS established inflammation as a modifiable cardiovascular target.

Low-dose colchicine 0.5 mg daily has emerged as a practical anti-inflammatory option. The LoDoCo2 trial (N=5,522) found a 31% reduction in the primary composite of cardiovascular death, MI, stroke, and ischemia-driven revascularization (hazard ratio 0.69, 95% CI 0.57 to 0.83, P<0.001) in patients with chronic coronary artery disease [16]. Patients with high CAC scores and persistently elevated hsCRP despite statin therapy may be appropriate candidates for colchicine, as discussed with a physician.

Aspirin: A More Complicated Picture

Low-dose aspirin was historically recommended broadly for primary prevention but the evidence has shifted. The ASPREE trial (N=19,114 adults ≥70 years) showed no significant reduction in cardiovascular events with aspirin 100 mg daily versus placebo, while bleeding events increased significantly [17]. Current ACC/AHA guidelines do not recommend aspirin for primary prevention in most patients. For secondary prevention in patients with established coronary artery disease and a CAC score ≥300, aspirin remains appropriate; the decision is individualized.

Supplements With Limited or Conditional Evidence

Vitamin K2

Vitamin K2 (menaquinone-7) activates Matrix Gla Protein, a calcium-binding protein that may inhibit arterial calcification. A 3-year Dutch RCT (N=244 healthy postmenopausal women) found that MK-7 supplementation at 180 mcg daily significantly reduced progression of carotid intima-media thickness and reduced arterial stiffness compared with placebo (P<0.05) [18]. Direct CAC score data in primary prevention trials are limited. Ongoing trials may clarify whether MK-7 measurably slows coronary calcium accumulation.

Omega-3 Fatty Acids

The REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid (EPA) 4 g/day (Vascepa) reduced the primary cardiovascular composite by 25% in statin-treated patients with elevated triglycerides [19]. The mechanism is not purely lipid-based; EPA may reduce oxidative stress and membrane lipid peroxidation in plaques. Whether this reduces CAC progression specifically is not yet established.

Magnesium

Low serum magnesium is associated with higher CAC scores in observational data from MESA, but supplementation trials targeting CAC as a primary endpoint are lacking. Magnesium deficiency is common in Western diets; repletion to normal serum levels (1.7 to 2.2 mg/dL) is reasonable given its role in vascular smooth muscle relaxation.

How Often Should CAC Be Rescanned?

Repeat CAC scanning more frequently than every 3 to 5 years adds radiation exposure without proportional clinical information for most patients. The Society of Cardiovascular Computed Tomography (SCCT) recommends a repeat scan no sooner than 5 years for patients with baseline scores below 100, and consideration at 3 to 5 years for those with scores of 100 to 399. For patients with scores ≥400 already on maximal therapy, rescanning rarely changes management and may not be warranted unless a specific clinical question requires it.

A practical decision framework for repeat scanning:

| Baseline CAC | Optimal Therapy in Place? | Suggested Rescan Interval | |---|---|---| | 0 | No | 5 years (if other risk factors exist) | | 1 to 99 | No | 3 to 5 years | | 100 to 399 | Yes (statin + lifestyle) | 3 to 5 years | | ≥400 | Yes | Rarely indicated; individualize |

What to Do When Your CAC Score Is Zero

A score of zero in a patient at intermediate cardiovascular risk has powerful negative predictive value. MESA data show a 10-year MACE event rate below 1% in adults with CAC=0, which led the 2019 ACC/AHA guidelines to explicitly support using a zero score to defer statin therapy [3]. However, a zero score in a heavy smoker with a family history of early MI does not mean zero risk: soft non-calcified plaque can cause events even when the CAC score is zero. Lifestyle optimization remains appropriate for anyone with cardiovascular risk factors regardless of score.

Monitoring Markers Beyond CAC

CAC alone does not capture the full cardiovascular picture. These additional markers guide treatment intensity between scans:

• LDL-C and non-HDL-C measured every 3 to 12 months on therapy, targeting LDL <70 mg/dL in patients with CAC ≥100
• ApoB is a more direct measure of atherogenic particle count than LDL-C, with a target below 80 mg/dL in high-risk patients per the National Lipid Association
• hsCRP greater than 2.0 mg/L after statin therapy identifies residual inflammatory risk and may support colchicine or further anti-inflammatory measures
• Lp(a) above 125 nmol/L (50 mg/dL) independently drives CAC progression and is largely statin-resistant; RNA-targeted therapies (pelacarsen, olpasiran) are in phase 3 trials
• HbA1c below 7.0% targets in diabetes, with GLP-1 agonists preferred when cardiovascular risk is high